QIAGEN stock forecast 2027–2029
MyStockButler's October 2026 analysis: The weighted forecast is €45.80 in October 2027, with the base case carrying 60% probability. It hinges on durable operating growth.
Where could QIAGEN's shares go?
The weighted forecast is €45.80 in October 2027, a +3% return. It reaches €48.71 in October 2029, a +10% return. The bear case has 25% probability. The base case has 60%, and the bull case 15%.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 25 % | 35.51 (-21 %) | 32.23 (-28 %) | 30.59 (-32 %) |
| Base | 60 % | 46.59 (+4 %) | 46.52 (+5 %) | 46.46 (+6 %) |
| Bull | 15 % | 59.82 (+34 %) | 72.90 (+64 %) | 87.89 (+99 %) |
| Weighted | 100 % | 45.80 (+3 %) | 46.90 (+6 %) | 48.71 (+10 %) |
What this means. The weighted row is the probability-based average of the bear, base, and bull cases, not a separate prediction.
What has to go right or wrong for QIAGEN?
The base earnings row therefore rises through the forecast, with margins recovering from 25.23% toward 26.37%. The bear row keeps earnings near $500 million because weak testing demand and poor instrument pull-through prevent operating leverage. The bull row reaches $720 million as QuantiFERON stabilizes, QIAstat-Dx panels broaden and QIAcuity consumables generate repeat use. The forecast excludes NeuMoDx, restructuring and exceptional tax effects, while retaining ordinary interest and taxes.
How much cash does QIAGEN really make?
Free cash flow means operating cash after purchases of property, plant and equipment. It is useful because it asks what remains after the business funds its operating needs and maintains or expands its physical base. It does not mean that interest, leases or restructuring are economically free; those costs may already have passed through operating cash.
Stock compensation is another owner cost. Issuing shares saves cash today but transfers part of the business to employees. Treating that cost as a deduction gives a stricter measure of cash available to owners.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 654,326 | 673,551 | 459,455 | 715,264 | 639,001 |
| − Capital spending | 201,049 | 167,174 | 149,710 | 129,224 | 189,904 |
| = Free cash flow | 453,277 | 506,377 | 309,745 | 586,040 | 449,097 |
| − Stock pay | 50,400 | 43,627 | 47,100 | 49,507 | 38,391 |
| = Real free cash flow | 402,877 | 462,750 | 262,645 | 536,533 | 410,706 |
What this means. The company's own free cash flow matches ours, but our real free cash flow is lower because shares given to employees as pay reduce shareholders' ownership even though they use no cash.
What does an investor pay for QIAGEN today?
The P/E ratio shows what investors pay for one year of earnings. QIAGEN trades at 25.4 times trailing US GAAP earnings and 19.3 times estimated adjusted earnings for the next twelve months. The lower forward multiple also reflects the change in earnings definition: QIAGEN's second-quarter 2026 diluted EPS was $0.50, while adjusted EPS was $0.62. The adjustment removed items including acquired-intangible amortization, restructuring and tax effects. Investors must ask whether profits improve because customers buy more products, rather than because more costs are excluded.
| Today (Oct 22, 2026) | |
|---|---|
| Share price | 44.935 |
| Market value (calculated) | 9,278.85 |
| P/E, last 12 months, US GAAP earnings (calculated) | 25.4x |
| P/E, next 12 months, adjusted earnings (calculated) | 19.3x |
| Real free cash flow yield (calculated) | 3.9% |